Clark et al. [61] tested wider dose ranges of lycopene supplementation (15–120 mg day−1) in 36 patients with biochemical relapse of prostate cancer, and found no stabilization of PSA levels as a consequence of the treatment. The gene discussed is KLK3; the disease is prostate carcinoma.